Switching on a subtype of the receptor that binds cannabis, the active ingredient in marijuana, can suppress inflammation -- suggesting a new and particularly promising target to treat autoimmune problems such as multiple sclerosis and the damage caused by immune cells after a stroke. But hotly contested evidence for whether or not this cannabinoid receptor is expressed on neurons may limit the potential for pursuing that target in the search for new medicines.
A cannabis tincture from the
first half of the 20th century

Image: Wikipedia
Understanding the receptor's role in damaged neurons and autoimmunity "has pretty important therapeutic implications," said linkurl:Ken Mackie,;http://www.indiana.edu/~gillctr/mackie.shtml a neuroscientist at Indiana University in Bloomington who studies cannabinoid receptors in the brain.It's commonly accepted that marijuana's "high" stems from cannabis binding to one type of cannabinoid receptor -- called the CB1 receptor -- which is widespread on neurons in the brain. Scientists have tied CB1...
Microvascular ResearchScienceBrain and ResearchNew York Academy of SciencesBrain and ResearchGenes, Brain and Behavior

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?